Cart
sales@molnova.com
NNC 92-1687
CAS No. 22903-37-3
NNC 92-1687( —— )
Catalog No. M34348 CAS No. 22903-37-3
NNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 603 | Get Quote |
|
| 5MG | 922 | Get Quote |
|
| 10MG | 1121 | Get Quote |
|
| 25MG | 1454 | Get Quote |
|
| 50MG | 1822 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameNNC 92-1687
-
NoteResearch use only, not for human use.
-
Brief DescriptionNNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.
-
DescriptionNNC 92-1687 is a selective glucagon receptor antagonist that can be used to study type 2 diabetes.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetGlucagon Receptor
-
RecptorGlucagon Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number22903-37-3
-
Formula Weight300.33
-
Molecular FormulaC15H12N2O3S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESS(CC(=O)C1=CC(O)=C(O)C=C1)C=2NC=3C(N2)=CC=CC3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Retatrutide
Retatrutide (LY3437943) is a triple agonist of the glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, and glucagon-like peptide-1 receptor (GLP-1R), and inhibits GCGR, GIPR, and GLP-1R.Retatrutide can be used to study obesity.
-
PF-06882961
PF-06882961 is an orally bioavailable glucagon-like peptide-1 receptor (GLP-1R) agonist. PF-06882961 shows mild to moderate damage to the heart, moderate to severe effects on the thymus gland (which helps with managing infection), mild to moderate stomach ulcers at the highest dose level given in the rat.
-
Glucagon-like peptid...
Glucagon-like peptide 1 (1-37), human is a highly potent agonist of the GLP-1 receptor.Pancreatic hormone synthesized by post-translational processing of proglucagon. Unlike truncated forms of GLP-1, it has no effect on food intake in rats and does not enhance pancreatic insulin secretion.
